1. Patients in the primaquine group reported a significant reduction in parasitemia risk at day 63 compared to those in the standard care group. 2. The majority of adverse events were mild-to-moderate with no treatment-related deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: In areas where Plasmodium vivax and Plasmodium falciparum coexist, there exists an